Search Results

Solid Biosciences Inc. announced that the Company has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of US equity markets, Monday, July 1st 2024.

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced grants of 30,949 restricted stock units to four newly hired employees.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Xcell Biosciences Inc. and AmplifyBio today announced the launch of a partnership designed to streamline and improve the manufacturing process for engineered T-cell receptor (TCR) therapies targeting solid tumors.

Solid Biosciences Inc. today announced participation in the following investor conferences.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical program updates for IDE397, a potential first-in-class Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors.

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced grants of 38,508 restricted stock units to two newly hired employees.

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced the grant of inducement awards to two newly hired employees.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical Officer, will present at Cantor’s Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET.

Pillar Biosciences, Inc., the leader in Decision Medicine™ today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Premarket Approval (PMA) supplement application for its oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD).